Cite
HARVARD Citation
Bartko, J. et al. (2018). A Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway. Clinical pharmacology & therapeutics. 104 (4), pp. 655-663. [Online].